Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm…
NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development, today announced that Mikael Dolsten,…
Event exploring the escalating threat of emerging infectious diseases Discussion covering going-private transaction with Aditxt, strategic growth partner HALIFAX, Nova…
Burlington, Ontario--(Newsfile Corp. - April 1, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today…
Following a successful Korea launch, MEPSGEN brings advanced microfluidic technology to U.S. researchersNanoCalibur™ offers precise, scalable, and reproducible nanoparticle production for drug developmentMEPSGEN's…
Stay on TASK Infographic Infographic describing the four steps to being able to get vaccinated with confidence described by TASK…
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of…
Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients…
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for…
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia…
